SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
Cancer Research UK · GlaxoSmithKline (United Kingdom) · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,653
total citations
- FWCI
- 10.81
- Percentile
- 100%
- References
- 44
Citations per year
Authors
8- GJGareth J. InmanCorresponding
Cancer Research UK, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), The Honourable Society of Lincoln's Inn
- FJFrancisco José Nicolás
GlaxoSmithKline (United States), Cancer Research UK, The Honourable Society of Lincoln's Inn, GlaxoSmithKline (United Kingdom)
- JFJames F. Callahan
GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom), The Honourable Society of Lincoln's Inn, Cancer Research UK
- JDJohn D. Harling
Cancer Research UK, GlaxoSmithKline (United States), The Honourable Society of Lincoln's Inn, GlaxoSmithKline (United Kingdom)
- LMLaramie M. Gaster
GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), The Honourable Society of Lincoln's Inn, Cancer Research UK
Topics & keywords
Topics
Keywords
- Signal transduction
- Activin receptor
- Cell biology
- Biology
- Kinase
- Janus kinase 1
- ACVR2B
- Activin type 2 receptors
No related works found for this paper.